According to a recent LinkedIn post from Research Grid, the company is emphasizing structural weaknesses in current clinical trial recruitment models. The post highlights data suggesting that 80–85% of trials miss enrollment projections and that nearly 30% of sites enroll no participants, attributing much of this to strategies that prioritize broad reach over contextual trust.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post suggests that community-based approaches, built around trusted local networks, may materially improve engagement and retention. It cites internal experience indicating a 145% increase in patient engagement when community partners are involved early, which could translate into faster, more representative trials and potentially stronger value propositions for sponsors.
For investors, the post implies that Research Grid is positioning its offering around solving a key cost and timeline driver in drug development. If its community-centric model consistently reduces enrollment risk, the firm could benefit from higher demand among biopharma and CRO clients seeking to de-risk trial execution and improve data quality.
The focus on trust, diversity, and retention also aligns with growing regulatory and payer scrutiny around representation in clinical research. This strategic positioning may support pricing power and longer-term client relationships, though the post does not provide quantitative financial metrics, customer counts, or revenue impacts to substantiate the commercial scale of these engagement gains.